Pigneux, Arnaud
Montesinos, Pau
Cong, Ze
Zhang, Xinke
Pownell, Anja K.
Wieffer, Heather
McKendrick, Jan
Brüggemann, Monika
Funding for this research was provided by:
Amgen
Article History
Received: 14 June 2018
Accepted: 28 October 2018
First Online: 12 November 2018
Ethics approval and consent to participate
: The Human Research Ethics Committee of the University of Technology, Sydney, Australia, granted ethics approval (reference number PRMA3610_2016_10), and all participants gave written informed consent before starting the survey.
: Not applicable.
: This survey was sponsored by Amgen Inc. ZC and XZ are employees and stock holders of Amgen Inc. AKP, HW, and JM are employees of PRMA Consulting Ltd. and do not have competing interests. PRMA Consulting was paid by Amgen to conduct the study and contribute to the manuscript preparation, and receives professional fees from a number of companies. PM receives consulting fees from Amgen and Pfizer, and is on the Speakers Bureau for Amgen and Novartis. AP receives consulting fees from Novartis, and is on the Speakers Bureau for Jazz, Abbvie, and Celgene. MB has received research grants from Amgen, Regeneron, and Affimed. MB also receives consulting fees from PRMA Consulting Limited, and is on the Speakers Bureau for Amgen, Hoffman-La Roche, Incyte, and Pfizer.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.